铋剂四联疗法对幽门螺杆菌阳性慢性胃炎患儿胃蛋白酶原、白介素水平及免疫功能的影响  

Effects of Bismuth Quadruple Therapy on Pepsinogen,Interleukin Levels and Immune Function in Children with Helicobacter Pylori-Positive Chronic Gastritis

作　　者：宋庆梅[1] 张晓[1] 徐瑞[1] SONG Qing-mei;ZHANG Xiao;XU Rui(the Third Department of Pediatrics,Nanyang First People s Hospital,Nanyang 473000,China)

机构地区：[1]南阳市第一人民医院儿三科,南阳473000

出　　处：《中国合理用药探索》2021年第6期62-66,共5页Chinese Journal of Rational Drug Use

摘　　要：目的:分析铋剂四联疗法对幽门螺杆菌(Hp)阳性慢性胃炎患儿胃蛋白酶原、白介素水平及免疫功能的影响。方法:选择2019年1月~2019年12月本院收治的65例Hp阳性慢性胃炎患儿作为研究对象,依据随机数字表法分为对照组(n=32)和研究组(n=33)。对照组予以奥美拉唑+阿莫西林+克拉霉素治疗,研究组在对照组基础上予以枸橼酸铋钾治疗。比较两组治疗前和治疗后胃蛋白酶原(胃蛋白酶原Ⅰ、胃蛋白酶原Ⅱ)、白介素(IL-6、IL-1β)水平及免疫功能(CD4^(+)T、CD8^(+)T、CD4^(+)T/CD8^(+)T),并统计Hp根除率、不良反应发生率。结果:(1)治疗后,两组胃蛋白酶原Ⅰ水平高于治疗前、胃蛋白酶原Ⅱ水平低于治疗前,且研究组胃蛋白酶原Ⅰ水平高于对照组、胃蛋白酶原Ⅱ水平低于对照组(P <0.05)。(2)治疗后,两组IL-6、IL-1β水平低于治疗前,且研究组低于对照组(P <0.05)。(3)治疗后,两组CD4^(+)T、CD4^(+)T/CD8^(+)T高于治疗前、CD8^(+)T低于治疗前,且研究组CD4^(+)T、CD4^(+)T/CD8^(+)T高于对照组、CD8^(+)T低于对照组(P <0.05)。(4)研究组Hp根除率(93.94%)高于对照组(71.88%,P <0.05)。(5)研究组不良反应发生率(12.12%)低于对照组(25.00%,P> 0.05)。结论:铋剂四联疗法治疗Hp阳性慢性胃炎患儿,能有效调节胃蛋白酶原、白介素水平,增强机体免疫功能,提高Hp根除率,安全性尚可。Objective: To analyze the effects of bismuth quadruple therapy on pepsinogen,interleukin levels and immune function in children with helicobacter pylori( Hp)-positive chronic gastritis. Methods: A total of 65 children with Hp-positive chronic gastritis in our hospital from January 2019 to December 2019 were selected as the study objects. They were divided into control group( n = 32) and study group( n = 33) according to the random number table method. The control group was treated with omeprazole + amoxicillin + clarithromycin,and the study group was treated with bismuth potassium citrate on the basis of the control group. The levels of pepsinogen( pepsinogen Ⅰ,pepsinogen Ⅱ),interleukin( IL-6,IL-1β),immune function( CD4^(+)T,CD8^(+)T,CD4^(+)T/CD8^(+)T) were compared between the two groups before and after treatment,and the Hp eradication rate and the incidence of adverse reactions were counted. Results:(1) After treatment,the level of serum pepsinogen Ⅰ was higher than before treatment,the level of serum pepsinogen Ⅱ was lower than before treatment,and the level of serum pepsinogen Ⅰ in the study group was higher than that in the control group,the level of serum pepsinogen Ⅱ was lower than that in the control group( P < 0. 05).(2) After treatment,the levels of IL-6 and IL-1β in the two groups were lower than before treatment,and the study group were lower than the control group( P < 0. 05).(3) After treatment,CD4^(+)T,CD4^(+)T/CD8^(+)T in the two groups were higher than before treatment,and CD8^(+)T was lower than before treatment,CD4^(+)T,CD4^(+)T/CD8^(+)T in the study group were higher than those in the control group,and CD8^(+)T was lower than that in the control group( P < 0. 05).(4) The Hp eradication rate in the study group( 93. 94%) was higher than that in the control group( 71. 88%,P < 0. 05).(5) The incidence of adverse reactions in the study group( 12. 12%) was lower than that in the control group( 25. 00%,P > 0. 05). Conclusion: Bismuth quadruple therapy in the treatment of children with

关 键 词：铋剂四联疗法 幽门螺杆菌阳性 慢性胃炎 胃蛋白酶原 白介素 免疫功能 

分 类 号：R975[医药卫生—药品]